Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Alexandra Munroe¹, Adam Huber ², Bianca Lang ³, Suzanne Ramsey ⁴ and Elizabeth Stringer ⁴, ¹Dalhousie University, Halifax, Nova Scotia, Canada, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³Dalhousie University - Halifax, Halifax, Canada, ⁴IWK Health Centre, Halifax, Canada
Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium
Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort
Tara McGrath¹, Jaime Guzman ², Lori Tucker ³, Natalie Shiff ⁴, Maryna Yaskina ⁵, Susan Tupper ⁶ and Dax Rumsey ⁷, ¹University of British Columbia, Vancouver, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, Canada, ³BC Children's Hospital, Vancouver, British Columbia, Canada, ⁴Florida, Gainesville, ⁵Women and Children's Research Institute, Edmonton, Canada, ⁶Saskatoon, Canada, ⁷University of Alberta, Edmonton, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…
Abstract Number: 181 • 2020 Pediatric Rheumatology Symposium
Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis
Sabrina Cavallo¹, ¹University of Montreal, Montreal, Canada
Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) can be difficult and lead to undesirable outcomes in terms of socio-professional…
Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium
Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile
Sara Concha¹, Pamela Morales ², Eduardo Talesnik ¹ and Arturo Borzutzky ¹, ¹Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, ²Department of Pediatric, Clinica Las Condes, Santiago, Chile
Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
Abstract Number: 115 • 2020 Pediatric Rheumatology Symposium
Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study
Kimberly Lewis¹, Nico Osier ², Patricia Carter ³, Christina Nguyen ⁴, Ruy Carrasco ⁵, Shelby Brooks ², Alexandra Garcia ⁶ and Stefano Tiziani ⁵, ¹The University of Texas at Austin, Austin, Texas, ²The University of Texas at Austin, Austin, ³University of Alabama, Tuscalossa, ⁴Ascension Seton Nursing Research, Austin, ⁵The University of Texas at Austin, Dell Medical School, Austin, ⁶The University of Texas at Austin, Dell Medical School, School of Nursing, Austin
Background/Purpose: The purpose of this study is to define the relationships between pain and carbohydrate metabolism in teens with active juvenile idiopathic arthritis (JIA), teens…
Abstract Number: 182 • 2020 Pediatric Rheumatology Symposium
Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood
Sabrina Cavallo¹, ¹University of Montreal, Montreal, Canada
Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) may be a difficult period with challenges in socio-professional integration and in…
Abstract Number: 047 • 2020 Pediatric Rheumatology Symposium
Patients with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics and Inception Cohorts
Yongdong Zhao¹, Timothy Beukelman ², Yukiko Kimura ³, Mara Becker ⁴, Sarah Ringold ⁵, Anne Dennos ⁶ and Laura Schanberg ⁷ for the CARRA investigators, ¹University of Washington, Seattle, ²University of Alabama at Birmingham, Birmingham, ³Hackensack Meridian School of Medicine, Hackensack, ⁴Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ⁵Seattle Children's, Seattle, ⁶Duke University, Durham, ⁷Duke University Hospital, DURHAM
Background/Purpose: In July 2015, the CARRA Registry was re-established as a multi-center observational study that collects essential data from patients with childhood-onset rheumatic diseases. The…
Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Natalie Shiff¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Yukiko Kimura ⁴, Dax Rumsey ⁵, Jennifer Schenfeld ⁶, Scott Stryker ⁷, Marinka Twilt ⁸ and Timothy Beukelman ⁹, ¹Florida, Gainesville, ²Duke University, Durham, ³Amgen, Thousand Oaks, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵University of Alberta, Edmonton, Canada, ⁶Amgen, Long Beach, ⁷Amgen, Inc, San Francisco, ⁸Alberta Children's Hospital, Calgary, Canada, ⁹University of Alabama at Birmingham, Birmingham
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
Abstract Number: 184 • 2020 Pediatric Rheumatology Symposium
A Survey of Uveitis Knowledge Among Juvenile Arthritis Patients and Parents
Ashley Cooper¹, Elaine Flanagan ², Tova Ronis ³, Baruch Goldberg ⁴, Ashley Sherman ¹, Chelsey Smith ⁵ and Gary Holland ⁶ for the CARRA investigators, ¹Children's Mercy Kansas City, Kansas City, ²Emory University, Atlanta, ³Children's National Hospital, Washington, ⁴UT Physicians, Houston, ⁵Children's Mercy Kansas City, Holden, ⁶
Background/Purpose: Chronic anterior uveitis is a sight-threatening complication of juvenile idiopathic arthritis (JIA). Prompt treatment to prevent complications requires regular screening and detection of uveitis…
Abstract Number: 048 • 2020 Pediatric Rheumatology Symposium
Novel Algorithm to Increase Sensitivity of Detecting Active Arthritis in Children Through Infrared Thermal Imaging
Yongdong Zhao¹, Ramesh Iyer ¹, Mahesh Thapa ¹, Debosmita Biswas ¹, Kevin Cain ¹, Savannah Partridge ¹ and Carol Wallace ¹, ¹University of Washington, Seattle
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. The use of infrared thermal imaging for screening JIA has not utilized…
Abstract Number: 121 • 2020 Pediatric Rheumatology Symposium
Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis
Emily Liebling¹, Walter Faig ², Nicholas Moore ¹, Nahomy Ledesma Vicioso ³ and Melissa Lerman ⁴, ¹Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, ²Children's Hospital of Philadelphia, Philadelphia, ³Weill Cornell Medical College, New York, New York, ⁴Philadelphia, Pennsylvania
Background/Purpose: JIA – associated uveitis (JIA-U) accounts for 20-40% of childhood noninfectious uveitis and affects 10-20% of patients with JIA. Its chronic course is often…
Abstract Number: 186 • 2020 Pediatric Rheumatology Symposium
Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases
Lucila Pereira¹, Agatha Nogueira Previdelli ², Rosana Gomes de Torres Rossi ², Wellington Douglas Rodrigues ³, Fernado Luiz Affonso Fonseca ³, Claudio Len ⁴, Roseli Oselka Saccardo Sarni ³ and Maria Teresa Terreri ⁴, ¹Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Sao Judas Tadeu University, Sao Paulo, Brazil, ³Federal University of Sao Paulo, Sao Paulo, Brazil, ⁴Sao Paulo, Brazil
Background/Purpose: Chronic rheumatic diseases in children and adolescents increase cardiovascular risk. Thus, knowing the eating habits, biomarkers of lipid metabolism and the lifestyle of patients…
Abstract Number: 049 • 2020 Pediatric Rheumatology Symposium
Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures
Danielle Fair¹, Judyann Olson ², Jan Lemke ³, Stella Protopapas ⁴, Ke Yan ⁵ and Jian Zhang ⁶, ¹Medical College of Wisconsin & Affiliated Hospitals: Children's Wisconsin, Wauwatosa, Wisconsin, ²Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ³Children's Wisconsin, Milwaukee, Wisconsin, ⁴Riley Children’s Hospital at Indiana University, Indianapolis, Indiana, ⁵Medical College of Wisconsin, Milwaukee, Wisconsin, ⁶Medical College of Wisconsin, 53226, Wisconsin
Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population. Children with JIA experience…
Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Sarah Kodama¹, Deepti Gupta ², Erin Sullivan ³ and Yongdong Zhao ⁴, ¹School of Medicine, Virginia Commonwealth University, Richmond, ²Pediatric Dermatology, School of Medicine, University of Washington, Seattle, ³Seattle Children's Research Institute, Seattle, ⁴University of Washington, Seattle
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
Abstract Number: 053 • 2020 Pediatric Rheumatology Symposium
Acceptability and Usability Testing of a Preliminary Version of the JIA Option Map, an Electronic Decision Aid for Pain Management Options in Juvenile Idiopathic Arthritis
Karine Toupin April¹, Adam Huber ², Ciaran Duffy ³, Deema Couchman ¹, Laurie Proulx ⁴, Esi Morgan ⁵, Fjolla Berbatovci ¹, Andrea Boyd ¹, Hannah Sachs ¹, Alexandra Sirois ⁶, Lucie Brosseau ³, Janice Cohen ⁷, Margaret Bisch ³, Aditi Sivakumar ¹, Marco Ragusa ¹, Tania El Hindi ⁸, Isabelle Gaboury ⁹, Linda Li ¹⁰, Elizabeth Stringer ¹¹, France Legare ¹², Sabrina Cavallo ¹³, Michele Gibbon ¹⁴, Paul Fortin ¹⁵, William Brinkman ⁵, Mark Connelly ¹⁶, Jennifer Weiss ¹⁷, Sabrina Gmuca ¹⁸, Peter Tugwell ¹⁹ and Jennifer Stinson ²⁰, ¹Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³Ottawa, Canada, ⁴Canadian Arthritis Patient Alliance, Ottawa, Canada, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Outremont, Canada, ⁷Children's Hospital of Eastern Ontario, Ottawa, Canada, ⁸Statistics Canada, Ottawa, Canada, ⁹University of Sherbrooke, Sherbrooke, Canada, ¹⁰University of British Columbia, Vancouver, Canada, ¹¹IWK Health Centre, Halifax, Canada, ¹²Laval University, Quebec City, Canada, ¹³University of Montreal, Montreal, Canada, ¹⁴Children's Hospital of Eastern Ontario RI, Ottawa, Canada, ¹⁵CHU de Quebec - Universite Laval, Quebec, Canada, ¹⁶Kansas City, ¹⁷Hackensack University Medical Center, Hackensack, ¹⁸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, ¹⁹University of Ottawa - Ottawa, Ottawa, Canada, ²⁰University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada
Background/Purpose: Although juvenile idiopathic arthritis (JIA) is one of the most common causes of chronic musculoskeletal pain among youth, families’ decision-making for pain management is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].